Statistics from Altmetric.com
The National Institute for Health and Clinical Excellence (NICE) issued guideline CG140 in May 2012, for professionals commencing strong opioids in adult palliative care patients.1 Although this guideline is for non-specialist professionals who initiate opioid treatment (eg, general practitioners and generalist hospital doctors), the implications for those working in specialist palliative care settings will be significant. It is important that NICE guidelines should facilitate and consolidate the ongoing dialogue between generalists and specialists in palliative care. Here, we summarise the recommendations to highlight areas that are of particular importance to specialist palliative care providers.
Development of this guideline followed the NICE process for short clinical guideline development.2 Recommendations within the guideline were made after systematic reviews had been conducted to consider the best available evidence. Where minimal evidence was available, the Guideline Development Group's experience and opinion of what constitutes good practice was debated, considered and summarised. The guideline takes effect at the point in time when a palliative care patient has moderate to severe pain, which necessitates commencing strong opioid analgesia. The guideline does not cover the last days of life, nor does it go further into recommendations for second-line approaches for pain control.
A number of key areas are addressed: communication, starting strong opioids (first-line treatment options, titrating the dose, maintenance phase and what to do when oral opioids are not suitable), management of breakthrough pain, and management of side effects (constipation, nausea and drowsiness). These are summarised in table 1.
The Guideline Development Group (GDG) highlighted that communication with patients starting opioids is often inadequate and should incorporate the …
Competing interests MT, MB and JR were members of the NICE Guideline Development Group (GDG) tasked with writing NICE Guideline CG140. The National Collaborating Centre for Cancer was commissioned and funded by the National Institute for Health and Clinical Excellence to write this summary; MB has received honorariums for lectures from Cephalon and Grünenthal in the past three years but not during the period when the guideline was being developed; there were no other relationships or activities that could appear to have influenced the submitted work.
Provenance and peer review Not commissioned; internally peer reviewed.
Correction notice This article has been corrected since it was published Online First. The following sections have been updated for grammatical purposes: 'The National Institute for Health and Clinical Excellence (NICE) issued guideline in May 2012,' now reads 'The National Institute for Health and Clinical Excellence (NICE) issued guideline CG140 in May 2012,'; 'While NICE guideline would not usually recommend doses,' now reads 'While NICE guidelines would not usually recommend doses,'; and the phrase 'to give inexperienced practitioners faced with a prescribing decision clearer guideline.' now reads 'to give inexperienced practitioners faced with a prescribing decision clearer guidance.'
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.